****New release August 2009***

DiseaseINFOPACK: Enterovirus-71 (CAT: VADIP015)

Proposal No/#PO	:	**[Enter client specific #PO]**
Product Name	:	Comprehensive review/analysis of Enterovirus-71 virus disease trends/dynamics
Project Initiation Date	:	n/a
Billable days	:	n/a
Initiator(s)	:	[Enter client name, function and address]
Therapeutic Area	:	*Emerging viruses/SE Asia*
Product (if applicable)	:	**CAT No:** VADIP015, published August 2009

Background

Enteroviruses are icosahedral nonenveloped viruses which are members of the *Picornaviridae* family of viruses. There are many types of *Enteroviruses* which in turn cause a wide range of infections in humans. The viruses, which are mainly spread by fecal and respiratory oral route can cause polio (poliovirus), viral heart disease and hand-foot and mouth disease (coxsackievirus Group A and Group B). *Enteroviruses* such as serotypes 68-71 are considered the "newer Enteroviruses" (1).

Enterovirus 71 (EV-71) is a common etiologic agent of hand-foot and mouth (HFM) disease which is mainly a disease of children <10 yrs. Although prodrome symptoms of HFM are self resolving, the EV-71 can also cause severe neurologic disease including encephalitis, meningitis, and polio-like paralysis. In particular EV-71 has caused epidemics in the Western pacific region such as Taiwan (1998), Singapore (2000) and China (2007) In the Taiwan epidemic 32% of cases experienced complications of which 6.8% involved fatal pulmonary edema (2). In July 2008, the Chinese CDC reported that 176,000 cases occurred in a single month (May) (3).

Because of its potential to cause mortality and severe morbidity in children, and regional significance, EV-71 appears a plausible target for a vaccine-based preventative approach. EV-71 is under consideration by a number of commercial manufacturers.

1) Sinha S., Enteroviruses. Emedicine from WebMD. Available at: http://emedicine.medscape.com/article/217146-overview. Accessed August 2009.
2) Chang LY, Lin TY, Huang YC, Tsao KC, Shih SR, Kuo ML, et al. Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. *Pediatr Infect Dis J*. Dec 1999;18(12):1092-6.
3) Chinese CDC. China's HFMD toll rises to 43 as girl in Jiangxi succumbs. 19th May 2008. Available at: http://www.chinacdc.net.cn. Accessed: August 2009

PRODUCT CONTENTS:

Published August 2009 (CAT No: VADIP015)

PAGES: ~60 MS Powerpoint slides, fully referenced/sourced. Available in .pdf form

PROJECT METHODOLOGY:

VacZine Analytics has conducted a comprehensive secondary research to review all available information regarding Enterovirus in major Western and SE Asia markets. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc.

PRODUCT PRICE:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- USD **$4895.00**/ GBP **£3265.00** (Region license)*

*A region is North America, Europe or ROW
For orders in the UK, VAT at 15% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.

BIBLIOGRAPHY:

1. Fox G et al. The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid). J Gen Virol. 1989 Mar;70 (Pt 3):625-37.
2. Tan CS et al. High-titred neutralizing antibodies to human enterovirus 71 preferentially bind to the N-terminal portion of the capsid protein VP1. Arch Virol. 2007;152(6):1069-73
3. Iwai M et al. Genetic Changes of Coxsackievirus A16 and Enterovirus 71 Isolated from Hand, Foot, and Mouth Disease Patients in Toyama, Japan between 1981 and 2007. Jpn J Infect Dis. 2009 Jul;62(4):254-9.
4. Li RQ et al. [Genetic characteristics of enterovirus 71 isolated in Beijing, 2006-2008]. Zhonghua Liu Xing Bing Xue Za Zhi. 2009 Jan;30(1):45-9.
5. Kung SH et al. Genetic and antigenic analyses of enterovirus 71 isolates in Taiwan during 1998-2005. Clin Microbiol Infect. 2007 Aug;13(8):782-7.
6. Arita M et al. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol. 2007 Sep;81(17):9386-95.
7. Mizuta K et al. Cross-antigenicity among EV71 strains from different genogroups isolated in Yamagata, Japan, between 1990 and 2007. Vaccine. 2009 May 21;27(24):3153-8.
8. Chinese Centre for Disease Control and Prevention and Office of the World Health Organization in China. Report on the Hand, foot, and mouth disease outbreak in Fuyang City, Anhui Province and prevention and control in China, May 2008. Available at: http://www.wpro.who.int/. Accessed: August 2009
9. Hand-foot-mouth disease spreading in China's Shandong, death toll at 44. China View,7 Jul 2009. Available at: http://news.xinhuanet.com. Accessed: August 2009
10. Sarawak Health Department, Ministry of Health Malaysia. Hand, foot and mouth disease. Available at: http://www.sarawak.health.gov.my. Accessed: August 2009
11. Update On Hand, Foot And Mouth Disease (HFMD) Situation In Singapore. 22 May 2008. Available at: http://www.moh.gov.sg. Accessed: August 2009.
12. Huang CC et al. Neurologic complications in children with enterovirus 71 infection. N Engl J Med. 1999 Sep 23;341(13):936-42.
13. Wong KT et al. The distribution of inflammation and virus in human enterovirus 71 encephalomyelitis suggests possible viral spread by neural pathways. J Neuropathol Exp Neurol. 2008 Feb;67(2):162-9.
14. Nishimura Y et al. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med. 2009 Jul;15(7):794-7.
15. Yamayoshi S et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med. 2009 Jul;15(7):798-801.
16. Luo ST et al. Enterovirus 71 maternal antibodies in infants, Taiwan. Emerg Infect Dis. 2009 Apr;15(4):581-4.
17. Diedrich S et al. Seroprevalence and molecular epidemiology of enterovirus 71 in Germany. Arch Virol. 2009;154(7):1139-42.
18. Lu M et al. [Pathology of enterovirus 71 infection: an autopsy study of 5 cases]. Zhonghua Bing Li Xue Za Zhi. 2009 Feb;38(2):81-5.
19. Chen TC et al. Enterovirus 71 triggering of neuronal apoptosis through activation of Abl-Cdk5 signalling. Cell Microbiol. 2007 Nov;9(11):2676-88.
20. Yang KD et al. Altered cellular but not humoral reactions in children with complicated enterovirus 71 infections in Taiwan. J Infect Dis. 2001 Mar 15;183(6):850-6.
21. Chang LY et al. HLA-A33 is associated with susceptibility to enterovirus 71 infection. Pediatrics. 2008 Dec;122(6):1271-6.
22. Chang LY et al. Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA. 2004 Jan 14;291(2):222-7.
23. Ooi MH et al. Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study. Clin Infect Dis. 2007 Mar 1;44(5):646-56.
24. Ho M et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med. 1999 Sep 23;341(13):929-35.
25. Hamaguchi T et al. Acute encephalitis caused by intrafamilial transmission of enterovirus 71 in adult. Emerg Infect Dis. 2008 May;14(5):828-30.
26. Zhang Y et al. An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J Clin Virol. 2009 Apr;44(4):262-7)
27. Global Polio Eradication Initiative Annual Report, 2008. Available at: http://www.polioeradication.org/. Accessed: August 2009
28. Chinese CDC. Health official: China HFMD outbreak peaks in May. 2008/06/16. Available at: http://www.chinacdc.net.cn. Accessed: August 2009.
29. Chinese CDC. China's HFMD toll rises to 43 as girl in Jiangxi succumbs. 2008/05/19. Available at: http://www.chinacdc.net.cn. Accessed: August 2009.

Warren House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44 (0) 1279 654514 e-mail: info@vacZine-analytics.com

30. Laboratory Virology and Serology Reporting Scheme - Monthly summary table. Available at: http://www.health.gov.au. Accessed: August 2009.
31. Australia's notifiable diseases status, 2005: Annual report of the National Notifiable Diseases Surveillance System. Available at: http://www.health.gov.au/. Accessed: August 2009.
32. McMinn P et al. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis. 2001 Jan 15;32(2):236-42
33. Prager P et al. Neurogenic pulmonary edema in enterovirus 71 encephalitis is not uniformly fatal but causes severe morbidity in survivors. Pediatr Crit Care Med. 2003 Jul;4(3):377-81.
34. Khetsuriani N et al. Enterovirus surveillance--United States, 1970-2005. MMWR Surveill Summ. 2006 Sep 15;55(8):1-20.
35. Fowlkes AL et al. Enterovirus-associated encephalitis in the California encephalitis project, 1998-2005. J Infect Dis. 2008 Dec 1;198(11):1685-91.
36. Pérez-Vélez CM et al. Outbreak of neurologic enterovirus type 71 disease: a diagnostic challenge. Clin Infect Dis. 2007 Oct 15;45(8):950-7
37. Witsø E et al. Asymptomatic circulation of HEV71 in Norway. Virus Res. 2007 Jan;123(1):19-29.
38. Bible JM et al. Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. J Clin Microbiol. 2008 Oct;46(10):3192-200
Shindarov, L. M. et al Epidemiological, clinical, and pathomorphological characteristics of epidemic poliomyelitis-like disease caused by enterovirus 71. J. Hyg. Epidemiol. Microbiol. Immunol. 1979. 23:284-295.
39. van der Sanden S et al. Epidemiology of Enterovirus 71 in the Netherlands, 1963-2008. J Clin Microbiol. 2009 Jul 22.
40. Huemer HP et al. Isolating Asian enterovirus 71 subgenogroup C4 in two Austrian clinical samples from 2004. Euro Surveill. 2008;13(28):pii=18922
41. Mirand A et al. [Rapid enterovirus genotyping in cerebrospinal fluids: a two-year prospective study in a virology laboratory setting] Pathol Biol (Paris). 2008 Nov-Dec;56(7-8):471-8.
42. Enterovirus surveillance. Available at: http://www.nlga.niedersachsen.de/ Accessed: August 2009.
43. Antona D et al. Surveillance of enteroviruses in France, 2000-2004. Eur J Clin Microbiol Infect Dis. 2007 Jun;26(6):403-12.
44. Chinese CDC. Boy found infected with EV71 in HK 2009/03/30. Available at: http://www.chinacdc.net.cn. Accessed: August 2009.
45. International Federation of Red Cross and Red Crescent Societies. Mongolia: Hand, Foot and Mouth Disease Outbreak DREF operation No. MDRMN001 Final report. Available at: http://www.reliefweb.int/. Accessed: August 2009.
46. International Surveillance Report. Reporting Period: 24 May 2008 – 6 June 2008 (ISR #12-08). Available at: www.health.gov.au. Accessed: August 2009
47. Sasidharan CK et al. Hand-foot-and-mouth disease in Calicut. Indian J Pediatr. 2005 Jan;72(1):17-21.
48. Chang LY et al. Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med. 2007 Mar 22;356(12):1226-34.
49. Huang MC et al. Long-term cognitive and motor deficits after enterovirus 71 brainstem encephalitis in children. Pediatrics. 2006 Dec;118(6):e1785-8.
50. New outbreak looming. Aug 23, 2008. Available at: http://www.straitstimes.com. Accessed August 2009.
51. Sinovac Investor Presentation, April, 2009. Available at: http://www.sinovac.com/. Accessed August 2009.
52. 2008 World Population Data Sheet. Population Reference Bureau. Available at: http://www.prb.org/. Accessed: August 2009.
53. Wu Z et al. Identification of small interfering RNAs which inhibit the replication of several Enterovirus 71 strains in China. J Virol Methods. 2009 Aug;159(2):233-8
54. Chen TC et al. Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71. Antimicrob Agents Chemother. 2009 Jul;53(7):2740-7.
55. Li ZH et al. Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. J Infect Dis. 2008 Mar 15;197(6):854-7.
56. Immuron Products and Pipeline. Available at: http://www.immuron.com/. Accessed: August 2009
57. WHO. Hand, foot and mouth disease a rising menace in Asia. 13 July 2009. Available at: Http://www.wpro.who.int/. Accessed: August 2009.
58. Chinese CDC. China warns of longtime regional outbreak of hand-foot-mouth disease. 2009/04/22. Available at: http://www.chinacdc.net.cn. Accessed: August 2009.
59. Chinese Centre for Health Protection. Letter to doctors, 3 April 2009. Available at: http://www.dh.gov.hk/. Accessed August 2009
60. Chinese CDC. Death toll of hand-foot-mouth disease rises to 25 in C China province. 2009/04/17. Available at: http://www.chinacdc.net.cn. Accessed: August 2009.
61. Enterovirus Infection with Severe Complications in Taiwan — Update 32, 2008. Available at: http://www.cdc.gov.tw/. Accessed: August 2009.
62. Enterovirus Infection with Severe Complications in Taiwan — Update 30, 2009. Available at: http://www.cdc.gov.tw/. Accessed August 2009.
63. Laboratory Surveillance. August 2009. Available at: http://www.cdc.gov.tw/. Accessed : August 2009.
64. The Communicable Disease Surveillance in Singapore (2000-2008). Available at: http://www.moh.gov.sg. Accessed: August 2009.

65. Weekly Infectious Disease Bulletin VOL. 6 NO.31 2009. Available at: http://www.moh.gov.sg. Accessed: August 2009.
66. Thai Department of Disease Control, Ministry of Public Health. National Disease Surveillance (Report 506).
67. Chan LG et al. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis. 2000 Sep;31(3):678-83.
68. Shekhar K et al. Deaths in children during an outbreak of hand, foot and mouth disease in Peninsular Malaysia--clinical and pathological characteristics. Med J Malaysia. 2005 Aug;60(3):297-304.
69. Podin Y et al. Sentinel surveillance for human enterovirus 71 in Sarawak, Malaysia: lessons from the first 7 years. BMC Public Health. 2006 Jul 7;6:180
70. Tu PV et al. Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Emerg Infect Dis. 2007 Nov;13(11):1733-41.
71. Hand-foot-mouth disease kills 10 children in Vietnam. May 2008. Available at: http://www.topnews.in/. Accessed: August 2009.
72. Hand-foot-mouth disease breaks out in the South. April 2009. Available at: http://english.vietnamnet.vn/. Accessed: August 2009.
73. Thu 14 May 2009. New virus outbreak kills girl in Korea. The Korea Herald. Available at: www.koreaherald.co.kr. Accessed: August 2009.
74. Korea Centers for Disease Control and Prevention. Pediatric Sentinel Surveillance Weekly Report. Number 25. Available from: http://www.cdc.go.kr. Accessed: August 2009.
75. Infectious Disease Surveillance Center. Hand, foot and mouth disease pathogens, 2005-2009. Available at: http://idsc.nih.go.jp/. Accessed: August 2009.
76. Infectious Disease Surveillance Center. EV71&CA16, 2005-2009. Available at: http://idsc.nih.go.jp/. Accessed: August 2009.
77. Fujimoto T et al. Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of enterovirus 71. Microbiol Immunol. 2002;46(9):621-7.
78. Infectious Disease Surveillance Center. Aseptic meningitis pathogens, 2005-2009. Available at: http://idsc.nih.go.jp/. Accessed: August 2009.
79. Infectious Agents Surveillance Report. Enterovirus infections in association with aseptic meningitis in Japan, as of December 2008. Vol. 30, No. 1 (No. 347); January 2009.

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein refered to as "The Company"). (Herein [enter client name] to as "The Client").

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.

2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.

3. Cancellation policy. The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.

4. Cancellation rights: For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.

5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.

6. If not purchased on-line invoices are payable within **thirty days** of the invoice date.

7. All proposals are quoted in **$USD dollars or £GBP** and invoices are to be settled in the same currency.

8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.

9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, influenza pandemic, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.

10. Please also refer to Master **TERMS and CONDITIONS** available upon request or at www.vaczine-analytics.com

VacZine Analytics
Of Assay Advantage Ltd
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

Warren House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44 (0) 1279 654514 **e-mail:** info@vacZine-analytics.com

Warren House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44 (0) 1279 654514 **e-mail:** info@vacZine-analytics.com